GLP-1 Weight Loss,
Done Right.

GLP-1 (Glucagon-Like Peptide-1) receptor agonists mimic your body’s natural satiety hormone. They activate receptors in the brain that control appetite, slow gastric emptying, and improve insulin sensitivity. Semaglutide and tirzepatide are the two most widely studied GLP-1 compounds.

Compounded semaglutide is prepared by FDA-registered 503B outsourcing facilities. It is not an FDA-approved finished product and is manufactured differently from branded medications. Your physician will explain the differences during your consultation. Compounded medications are typically not covered by insurance.

GLP-1 therapy is generally appropriate for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition. A licensed physician reviews your complete medical history during the assessment to determine if GLP-1 therapy is right for you.

The most common side effects are gastrointestinal: nausea, diarrhea, and constipation. These are typically mild, transient, and most common during the initial dose escalation period. Your physician starts at a low dose and gradually increases to minimize side effects.

Most patients notice reduced appetite within 1-2 weeks. Measurable weight loss typically begins within 2-4 weeks. Clinical trials showed the most significant results over 3-6 months of consistent treatment.

Your program includes a free physician assessment, personalized treatment plan, compounded GLP-1 medication from a 503B pharmacy, ongoing physician monitoring, 24/7 care team access, and free shipping. No insurance required.